Plasvacc Holdings

Plasvacc is a leading biotechnology company specializing in the production of high-quality hyperimmune plasma for the veterinary industry. The company operates specialized donor herds to manufacture biological products that provide passive transfer of immunity to animals, primarily horses, dogs, and camels. Their flagship products, such as Equiplas and Caniplas, are used globally by veterinarians to treat conditions like failure of passive transfer in foals, endotoxemia, and parvovirus. With manufacturing facilities in Australia and the United States, Plasvacc maintains rigorous quality control standards to ensure the safety and efficacy of its life-saving treatments. The company's focus on specialized immunotherapy makes it a critical provider in the equine and companion animal healthcare sectors.